TX-MAVENIR
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced the collaboration with Aspire Technology (Aspire), a specialized Network Solutions developer and System Integrator, to accelerate the market availability of O-RAN split 7.2 compliant Remote Radiohead Units (RRUs) leveraging Aspire’s Open Networks Lab in Europe.
Communication Service Providers (CSPs) demand for integrated high performing Open Radio Access Network (Open RAN) solutions based on Mavenir O-RAN compliant cloud-native Centralized Unit (CU) and Distributed Unit (DU) RAN software stacks is growing fast, fueled by modernization and coverage expansion projects, as well as private networks and indoor projects.
The number of O-RAN compliant RRUs from partners globally is also growing with sophisticated products across the different radio technologies, including Massive MIMO (mMIMO) and millimeter Wave (mmWave).
Mavenir and Aspire will be leveraging Aspire’s Open Networks Lab in Dublin for third-party RRU integration and testing. Furthermore, RRU vendors will be able to engage directly with Aspire and fast-track the integration and testing of new O-RAN compliant radios and frequency variants with Mavenir CU/DU software.
This collaboration will benefit not only RRU vendors, but also CSPs by expanding the offering of innovative and high-performing solutions supporting a wide number of use cases.
“This partnership greatly enhances the capacity to integrate and test RRUs with Mavenir’s CU/CU for 4G and 5G,” said Puneet Sethi, SVP/GM RAN Business for Mavenir. “Open RAN has accelerated to a point that we need to continuously innovate to be ahead of demand, including go-to-market models. Our RRU partners want to get their newest products available for deployment, and CSPs want to take full advantage of a fast-paced ecosystem minimizing integration and testing effort. We are continuously expanding our partner eco-systems for RRU integration to respond to the evolving market needs with specialized high-quality services and fast turnaround.”
Declan Friel, CTO, Aspire said; “We are delighted to extend our relationship with Mavenir. Aspire’s heritage in software engineering and testing of complex radio products carried over into Open RAN, combined with global CSP experience through design, optimization and support of live networks, uniquely positions us to accelerate the availability of new ORAN compliant solutions for wide market adoption. As a European-based independent company, and with our Open Networks Lab in Ireland today supporting a number of global clients and partners, our focus has been to accelerate the ORAN ecosystem development and to support CSPs. This will allow them to fully realize the benefits of Telco Cloud, Service Management & Orchestration and Open RAN, in terms of flexibility, performance and cost.”
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About Aspire:
Aspire Technology is a leading Specialized System Integrator with a long history and experience in fixed and mobile networks, and Open RAN since its early days. Aspire’s clients are spread around the Globe and benefit from their advanced services and software automation solutions. The Aspire Open RAN Lab enables technology partners and communications service providers to fasttrack development, integration, benchmarking, testing and deployment of Open RAN based networks and solutions. Aspire has been actively contributing to acceleration of time to market, reduction of deployment cost and improvement of multivendor interoperability and network performance. www.aspiretechnology.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005063/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nexo Becomes First-Ever Title Partner of the U.S. ATP 500 Dallas Open in Multi-Year Deal13.1.2026 16:30:00 CET | Press release
The agreement builds on Nexo’s long-term approach to partnerships with established global sports institutions. Nexo, the digital assets wealth platform, has been named the U.S. ATP 500 Dallas Open’s first-ever Title Partner under a multi-year agreement beginning in 2026, as the company advances its long-term brand strategy through leading global sports properties. The partnership was unveiled in Dallas alongside the debut of the Nexo Dallas Open brand and the resurfacing of two public tennis courts in North Texas. As one of only two ATP 500 tournaments in the U.S. and the country’s sole indoor ATP Tour championship, the Dallas Open places Nexo among a limited group of ATP 500 title partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113901822/en/ The Nexo Dallas Open “This partnership with Nexo represents a transformative milestone for the Dallas Open,” said Tournament Director Peter Lebedevs. “Securing a title spons
Blue Matter Establishes New Capabilities in Biopharma Research & Development Led by Partner, Tara Austraat-Churik13.1.2026 15:01:00 CET | Press release
Blue Matter is pleased to announce that it has established a practice area dedicated to serving clients in biopharmaceutical Research & Development (R&D). The practice is led by Tara Austraat-Churik, a Partner who joined the firm in September 2025. Tara Austraat-Churik has been serving life science clients for more than 20 years. Her areas of expertise include strategy development and implementation, operating model and organizational design, and process optimization in R&D and Medical Affairs. Prior to joining Blue Matter, she served as Managing Director in R&D, Health, Science, and Wellness at EY. She has a robust background in consulting, which also includes roles at Booz Allen Hamilton, Navitas, WPP, and IBM. She holds a BA and MA from the University of Notre Dame and an MSc in Translational Medicine from the University of Edinburgh. The R&D practice, according to Austraat-Churik, exists to help biopharma companies simplify and accelerate the pathway to market. She adds, “R&D organ
Wasabi Raises $70M in New Equity to Power the Next Era of Data Infrastructure13.1.2026 15:00:00 CET | Press release
At a $1.8 billion valuation, backed by L2 Point and Pure Storage, the company scales AI-first cloud storage to meet the explosive demands of modern data Wasabi Technologies, the Hot Cloud Storage company, today announced a $70 million equity funding round led by L2 Point Management with participation from Pure Storage and existing investors including Fidelity Management & Research Company. The new round values Wasabi at $1.8 billion and brings the company’s total funding to over $600 million. The capital will be used to accelerate Wasabi’s expansion into AI infrastructure, broaden its global footprint, and enhance its product portfolio to meet the growing data demands of enterprises and AI developers worldwide. “We’re ushering in the next generation of cloud storage, powering data-intensive workloads like generative AI and autonomous systems,” said David Friend, co-founder and CEO of Wasabi Technologies. “This funding underscores Wasabi’s strong market position and continued growth as
HumanX Amsterdam Reveals First 100 Speakers, Bringing Global AI Powerhouses to Europe13.1.2026 14:00:00 CET | Press release
Anton Osika (Lovable), May Habib (Writer), Jan Oberhauser (n8n) & Eléonore Crespo (Pigment) headline a diverse lineup spanning AI innovation and enterprise adoption HumanX, the global AI summit for executives and innovators, today unveiled its first 100 speakers and opened registration for HumanX Amsterdam, taking place 22–24 September 2026 at The RAI. Built by the team behind Money20/20, Shoptalk, and HLTH, HumanX Amsterdam brings the proven formula of its #1 U.S. flagship event and ecosystem gathering to Europe. The event convenes over 2,500 senior leaders focused on moving beyond the hype to drive practical, responsible AI implementation across industries. Speakers Leading the Conversation The first 100 speakers include AI company founders such as Anton Osika (Lovable), Jan Oberhauser (n8n), May Habib (Writer), Arvind Jain (Glean), and Jarek Kutylowski (DeepL), alongside executives scaling AI in the enterprise, including Clay Bavor (Sierra), Des Traynor (Intercom), and Eléonore Cres
GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug13.1.2026 14:00:00 CET | Press release
The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced that they have entered into a collaboration and license agreement to pursue the development of Debio1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae. With 82 million new cases each year, and the continued spread of multidrug-resistant N. gonorrhoeae strains, gonorrhea represents a global health crisis. This new partnership will help ensure that gonorrhea continues to be a treatable disease and will alleviate the risk of the emergence of future resistance, by ensuring that the antibiotic pipeline continues to be replenished. Gonorrhea caused by N. gonorrhoeae is currently in danger of becoming untreatable because of antimicrobial resistance (AMR). Having developed resistance to almost all antibiotics used to treat it, only one last recommended treatment, ceftriaxone, remains effective, and now we are seeing a growing number of cases that are
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom